Finance

Lists
C5G:FRA
Orexo AB
€1.34
+1.67%
(+0.022) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for C5G...
Open
€1.34
High
€1.34
Low
€1.34
Mkt. cap
531.82M
Avg. vol.
27.00
Volume
0.00
52-wk high
€3.82
52-wk low
€1.13
No. of employees
61
Open
€1.34
High
€1.34
Low
€1.34
Mkt. cap
531.82M
Avg. vol.
27.00
Volume
0.00
52-wk high
€3.82
52-wk low
€1.13
No. of employees
61
Profile
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners. Wikipedia
About Orexo AB
CEONikolaj Sørensen
Employees61
Founded1995
Headquarters-
SectorPharmaceutical industry
Websiteorexo.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
118.70M
3.30M
5.00M
3.50M
Cost of goods sold
7.10M
2.60M
500.00K
100.00K
Cost of revenue
7.10M
2.60M
500.00K
100.00K
Research and development expenses
61.70M
55.60M
50.10M
53.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
71.90M
28.00M
37.40M
58.20M
Operating expense
132.51M
80.70M
80.20M
106.50M
Total operating expenses
139.61M
83.30M
80.70M
106.60M
Operating income
-20.91M
-80.00M
-75.70M
-103.10M
Other non operating income
-200.00K
-200.00K
-100.00K
-300.00K
EBT including unusual items
-32.70M
-115.50M
-104.20M
-102.30M
EBT excluding unusual items
-32.71M
-93.50M
-104.50M
-103.00M
Income tax expense
-2.90M
100.00K
1.00M
200.00K
Effective tax rate
8.87%
-0.09%
-0.96%
-0.20%
Other operating expenses
-1.09M
-2.90M
-7.30M
-5.10M
Net income
-29.80M
724.80M
-133.90M
-100.40M
Net profit margin
-25.11%
21,963.64%
-2,678.00%
-2,868.57%
Earnings per share
-
-
-
-2.53
Interest and investment income
800.00K
600.00K
4.40M
2.00M
Interest expense
-11.30M
-12.20M
-32.90M
-
Net interest expenses
-10.50M
-11.60M
-28.50M
2.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.61M
-46.80M
-66.90M
-94.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps